You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Become a Subscriber
Subscribe•You
- manufacturingchemist.com (1 User) - access to exclusive content.
- Manufacturing Chemist magazine (both print and digital).
- Discounted tickets to attend relevant conferences.
Subscribe•Your Team
- manufacturingchemist.com (multi-user) - access to exclusive content.
- Manufacturing Chemist magazine (both print and digital).
- Discounted group tickets to attend relevant conferences.
Get access to subscriber exclusive breaking news, interviews, technical reviews and long form features, covering the entire industry.
More stories
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Reaching resilience: why pharmaceutical manufacturing needs battery energy storage systems
In a fast-changing energy landscape, Steve Ennis, Manufacturing Sector Manager for Aggreko, discusses the potential for battery energy storage systems (BESS) to address grid power shortages, fluctuating energy costs and increasing sustainability pressures
Sustainability
Merck launches first bio-based HPLC solvent portfolio with lower CO2 emissions than fossil-fuel alternatives
The new patent-pending portfolio of renewable solvents for high-performance liquid chromatography offers replacements for acetonitrile, methanol and ethanol that reduce carbon emissions while maintaining performance
Ingredients
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
Inhaled therapies advance as clinical trial data signal progress on two respiratory fronts
Two separate clinical programmes have reported encouraging progress in the development of inhaled therapies for respiratory conditions, with positive data emerging from trials targeting viral infection prevention and cystic fibrosis (CF)
Research & Development
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
The pair will advance their strategic partnership to the next phase of clinical trials for Brainomix's e-Lung after strong initial results demonstrated its potential to enable earlier diagnosis of progressive pulmonary fibrosis
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
MC EXCLUSIVE: MHRA on a mission to redefine UK gene therapy
The UK's medicines regulator is seeking industry input on a landmark overhaul of gene therapy medicinal product definitions — the first substantive update in more than two decades — as synthetic mRNA and CRISPR-based technologies outpace the legal framework designed to govern them
Finance
Bora Group to acquire MacroGenics’ manufacturing operations and CDMO business
The purchase will hand the Group a biologics drug substance manufacturing facility and a warehousing centre in Maryland, which Bora plans to use in cooperation with Tanvex Biopharma to scale its end-to-end biologics platform
Manufacturing
Shilpa Medicare signs commercial biologics manufacturing agreement with NXI Therapeutics
The strategic partnership will see Shilpa provide development and manufacturing support for Swiss-based NXI Therapeutics, positioning it as a lifecycle partner for NXI's immunomodulatory programmes
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)
Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework
Featured companies
Anton Paar
Anton Paar understands the need for completely traceable results and supports customers with a qualification and validation package following the 4Q model which fulfills the...
Lonza
As a dedicated CDMO serving the healthcare industry, we bring life-enhancing and life-saving treatments to market for our customers and their patients. We are a pioneer and...
Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life...
NSF
Founded in 1944, NSF’s mission is to protect and improve global human health. NSF, Pharmaceutical Services provides a comprehensive range of independent, third-party...
Resource Centre
About Manufacturing Chemist
Manufacturing Chemist
Through digital, live and print products, Manufacturing Chemist informs and inspires business leaders and decision-makers around the world. With a digital-first strategy, the Group’s Editors write breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry from ingredients and packaging to regulation, retail and marketing.
Pharma 5.0
Pharma 5.0 represents a paradigm shift in pharmaceutical manufacturing, paving the way for a future where medications are developed faster, customised to individual patient needs and delivered with uncompromising quality. It is not just about innovation; it is about transforming the way we think about healthcare and ultimately improving the lives of patients around the world.